VPRIV

VPRIV is a brand name of velaglucerase alfa, approved by the FDA in the following formulation(s):

VPRIV (velaglucerase alfa - injectable; iv (infusion))

• 
  Manufacturer: SHIRE HUMAN GENETIC
  
  Approval date: February 26, 2010
  
  Strength(s): 400 UNITS/VIAL
  

Has a generic version of VPRIV been approved?

No. There is currently no therapeutically equivalent version of VPRIV available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of VPRIV. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with VPRIV.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 26, 2015 - NEW CHEMICAL ENTITY
  
  

See also...

• VPRIV Consumer Information (Drugs.com)
• Vpriv Consumer Information (Wolters Kluwer)
• VPRIV Consumer Information (Cerner Multum)
• VPRIV Advanced Consumer Information (Micromedex)
• Velaglucerase alfa Consumer Information (Wolters Kluwer)
• Velaglucerase alfa Consumer Information (Cerner Multum)
• Velaglucerase alfa Intravenous Advanced Consumer Information (Micromedex)